All In Biotech

Drug Trial Radar · NCT00986154

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

Last checked: Nov 20, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,292 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,292

Actual

Start

Oct 2009

Primary completion

Apr 2013

Study completion Apr 2013

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.

Conditions

  • Venous Thromboembolism
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Thromboembolism
  • Venous Thrombosis

Interventions

  • edoxaban tosylate(DU-176b)Drug

    edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment

  • low molecular weight heparin/unfractionated heparinDrug

    LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily. Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment

  • warfarinDrug

    tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PETime frame: 12 months from time of randomization

Locations

454 sites in 38 countries. Site status is shown where the registry gives one.

  • Investigational Site 7103

    Mobile, Alabama

  • Investigational Site 7132

    Montgomery, Alabama

  • Investigational Site 7126

    Phoenix, Arizona

  • Investigational Site 7139

    Little Rock, Arkansas

  • Investigational Site 1070

    Anaheim, California

  • Investigational Site 7125

    Los Alamitos, California

  • Investigational Site 1093

    Monterey, California

  • Investigational Site 1069

    Palm Springs, California

  • Investigational Site 7150

    San Diego, California

  • Investigational Site 1089

    Vista, California

  • Investigational Site 1012

    Aurora, Colorado

  • Investigational Site 1013

    Boulder, Colorado

  • Investigational Site 1017

    Denver, Colorado

  • Investigational Site 1018

    Lakewood, Colorado

  • Investigational Site 1019

    Littleton, Colorado

  • Investigational Site 1022

    Thornton, Colorado

  • Investigational Site 1023

    Thornton, Colorado

  • Site not named

    Brandon, Florida

  • Investigational Site 1071

    Clearwater, Florida

  • Investigational Site 7117

    Fort Myers, Florida

  • Investigational Site 7106

    Gainesville, Florida

  • Investigational Site 1005

    Ocoee, Florida

  • Investigational Site 1006

    Orlando, Florida

  • Investigational Site 7144

    Sarasota, Florida

  • Investigational Site 7127

    St. Petersburg, Florida

  • Investigational Site 1007

    Winter Park, Florida

  • Investigational Site 7104

    Albany, Georgia

  • Investigational Site 1095

    Columbus, Georgia

  • Investigational Site 1080

    Jonesboro, Georgia

  • Investigational Site 7146

    Savannah, Georgia

  • Investigational Site 1098

    Park Ridge, Illinois

  • Site not named

    Carmel, Indiana

  • Investigational Site 7115

    Paducah, Kentucky

  • Investigational Site 1065

    Covington, Louisiana

  • Investigational Site 1068

    Baltimore, Maryland

  • Investigational Site 1037

    Westminster, Maryland

  • Investigational Site 1038

    Westminster, Maryland

  • Investigational Site 7133

    Kansas City, Missouri

  • Investigational Site 7147

    Butte, Montana

  • Investigational Site 1039

    Las Vegas, Nevada

Showing 40 of 454 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.